AI empowers the CGT track, Lianwu Jinnuo seeks angel round financing
Policy Dividends Unleash the CGT Track, but the Industry is Caught in the Dilemma of High Costs and Homogeneous R & D
The birth of Lianwu Jinnuo is rooted in the historical opportunity of the CGT industry's development. After the release of the 818 Cell and Gene Therapy Industry Policy in 2025, the domestic ATMPs (Advanced Therapy Medicinal Products) track, which had been dormant for many years, welcomed a clear direction for compliant development. The industry's demand for efficient and low - cost R & D tools has skyrocketed. The core technical team has been deeply involved in the CGT field for more than a decade and is well aware of the industry's pain points: Under the traditional R & D model, it takes an average of more than 6 years for an ATMP product to go from target discovery to IND application, and the R & D cost often reaches hundreds of millions of yuan, which is unaffordable for most small and medium - sized players. At the same time, most teams focus on popular targets, and the technical paths are highly homogeneous. Most pipelines struggle to achieve differentiated competition, and many R & D projects are stuck in the "valley of death" of pre - clinical transformation. Based on the more than a decade of technical and industrial accumulation of several partners, Lianwu Jinnuo officially launched the project in early 2026. With the vision of "making intelligent biotechnology benefit more people", it aims at the direction of AI - empowered CGT R & D and focuses on the development, transformation and services of ATMPs products such as exosome IVD, engineered exosomes, and AAV gene therapy.
More than a Decade of Industrial Experts Team Up to Start a Business, and Lianwu Jinnuo Aims at AI to Reconstruct the CGT R & D Paradigm
The project has completed the full - cycle construction from concept to implementation, and built a composite core team covering R & D and commercialization. On the industrial side, there are senior medical commercial operation talents, and on the scientific research side, high - level experts from domestic and overseas universities are gathered, responsible for the intelligent diagnosis platform, engineered vector drugs, and cell therapy process development respectively. The team has overcome three types of common problems in the industry: technology, large - scale production, and intellectual property rights. It has linked up with universities to build a closed - loop algorithm experiment, improved the standardized process system, and completed the confirmation of core patents. Now, an AI - driven CGT R & D platform has been launched, the self - developed targeted pipeline has completed pre - clinical verification, the supporting patent layout has been implemented, the industry - university - research cooperation is progressing steadily, and the platform's business model has been initially verified and formed.
AI Full - Process Automated R & D Platform: 3 - Fold Increase in Efficiency and 60% Direct Reduction in Costs to Build a Technical Barrier
Technically, Lianwu Jinnuo has built an AI - driven closed - loop for cost - reduction and efficiency - improvement in CGT R & D, forming a clear differentiated barrier. Different from the traditional R & D model of manual trial - and - error, Lianwu Jinnuo's AI platform can automate the entire process of target verification, vector optimization, and delivery system screening, which can increase the R & D efficiency by more than 3 times and reduce the R & D cost of a single project by 60%. To address the industry's homogeneity problem, the team focuses on the differentiated optimization of exosome targeted delivery and AAV vectors, and uses AI to achieve molecular - level precise design, building a technical barrier that is difficult to replicate. In terms of the commercialization path, the project adopts a dual - wheel - driven model of "pipeline + platform". It not only lays out self - developed pipelines that can be quickly implemented but also opens the platform to provide R & D services for the industry, breaking the dilemma of tight cash flow faced by most CGT start - ups.
Dual - Wheel - Driven "Pipeline + Platform" Model, Diverse Profit Models Solve the Cash Flow Problem of Start - ups
In terms of business model, Lianwu Jinnuo has built a diverse profit model of "technology platform as the foundation, service monetization + pipeline value - added + ecological collaboration": By providing AI - driven CGT R & D services to scientific research institutions and pharmaceutical companies and charging technical service fees, the real - world data obtained can be fed back to optimize the AI model, forming a positive cycle of "service - data - model" to ensure stable early - stage cash flow. Relying on the platform's capabilities, it can quickly promote the development of differentiated pipelines, and realize the value - added of pipelines through clinical advancement, licensing cooperation, or self - developed commercialization, opening up the long - term growth ceiling. By binding customers through platform services, it expands the integrated CRO business, forms the full - chain service ability of R & D - production - clinical, and at the same time reduces the R & D and production costs of its own pipelines, building a long - term competitive barrier.
A Blue Ocean Market Worth Billions Has Emerged, and the Industry - University - Research Verification and Implementation Accelerate the Angel - Round Financing
According to industry reports, it is predicted that the global CGT market will exceed 100 billion US dollars in 2030, and the domestic market will also exceed 100 billion yuan. As an emerging track, AI - empowered CGT R & D is still in the early stage of development and has huge growth potential. Lianwu Jinnuo is currently in the seed - round financing stage. In the future, it will accelerate the pre - clinical research of self - developed pipelines, expand the scale of platform service customers, plan to start the next - round financing at an appropriate time, gradually improve the full - chain service ability, and promote more AI - optimized ATMP products to be launched earlier to benefit patients.
The R & D leaders of several scientific research institutions involved in the early - stage docking said that Lianwu Jinnuo's AI platform has significantly reduced the trial - and - error cost of CGT R & D, which has provided great assistance for research groups to promote the research of innovative targets. The prediction accuracy of the platform meets expectations, and they plan to carry out in - depth cooperation in the future. When talking about the experience of starting a business, the founder, Lian Wei, said that CGT is a direction that can truly change the treatment pattern of many difficult diseases. In the past decade, the industry has accumulated a large number of technical achievements, but lacks efficient transformation tools. AI can just make up for this shortcoming. Being able to solve real problems in the industry with a group of partners who have been deeply involved in the field for many years, although there are many uncertainties in the process of starting a business, it is worth all the efforts to promote the progress of the industry.